Composition comprising recombinant Gplbα receptor protein
AssigneeF. Hoffmann-La Roche AG
InventorsElizabeth Booth, Virginia Montanini, John A. Hall, Jody Berry
Life of this patent
Estimating the term…
Abstract
Various aspects of the invention relate to recombinant polypeptides that specifically bind human von Willebrand Factor. Such recombinant polypeptides typically include a modified extracellular domain of platelet glycoprotein lbα that typically comprises at least one mutation selected from G233T, D235V, and K237V, and such recombinant polypeptides optionally include an oligomerization domain.
Claims24
A recombinant polypeptide that specifically binds human von Willebrand Factor, comprising a subunit comprised of a modified extracellular domain of platelet glycoprotein lbα, wherein:
- the modified extracellular domain comprises at least one mutation selected from G233T, D235V, and K237V, relative to SEQ ID NO:
- 19, wherein the modified extracellular domain has at least 95% sequence identity with an amino acid sequence selected from the group consisting of:
- SEQ ID NO:
- 2;
- SEQ ID NO:
- 3;
- SEQ ID NO:
- 4;
- and SEQ ID NO:
- 5.
A method for detecting von Willbrand disease in a subject, comprising:
- (a) obtaining a plasma sample from a subject;
- (b) incubating the sample or a dilution thereof with a recombinant polypeptide, the recombinant polypeptide comprising a subunit comprised of a modified extracellular domain of platelet glycoprotein lbα, wherein the modified extracellular domain comprises at least one mutation selected from G233T, D235V, and K237V, relative to SEQ ID NO:
- 19 and wherein the modified extracellular domain has at least 95% sequence identity with an amino acid sequence selected from the group consisting of:
- SEQ ID NO:
- 2;
- SEQ ID NO:
- 3;
- SEQ ID NO:
- 4;
- and SEQ ID NO:
- 5;
- and,
- (c) detecting the binding of von Willbrand factor (vWF) from the plasma sample or dilution thereof to the recombinant protein, wherein a defect in vWF as compared to a reference is indicative that the subject has type 1, type 2B, or type 3 von Willebrand disease.
Dependencies are inferred from the claim text.